Lucid Diagnostics Statistics
Share Statistics
Lucid Diagnostics has 59.34M shares outstanding. The number of shares has increased by 25.91% in one year.
Shares Outstanding | 59.34M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 3% |
Owned by Institutions (%) | n/a |
Shares Floating | 24.38M |
Failed to Deliver (FTD) Shares | 645 |
FTD / Avg. Volume | 0.16% |
Short Selling Information
The latest short interest is 422.42K, so 0.78% of the outstanding shares have been sold short.
Short Interest | 422.42K |
Short % of Shares Out | 0.78% |
Short % of Float | 2.22% |
Short Ratio (days to cover) | 1.52 |
Valuation Ratios
The PE ratio is -1.12 and the forward PE ratio is -1.45.
PE Ratio | -1.12 |
Forward PE | -1.45 |
PS Ratio | 24.25 |
Forward PS | 3.1 |
PB Ratio | -25.48 |
P/FCF Ratio | -1.78 |
PEG Ratio | n/a |
Enterprise Valuation
Lucid Diagnostics Inc. has an Enterprise Value (EV) of 55.24M.
EV / Earnings | -1.05 |
EV / Sales | 22.75 |
EV / EBITDA | -1.11 |
EV / EBIT | -1.14 |
EV / FCF | -1.67 |
Financial Position
The company has a current ratio of 0.75, with a Debt / Equity ratio of -6.04.
Current Ratio | 0.75 |
Quick Ratio | 0.74 |
Debt / Equity | -6.04 |
Total Debt / Capitalization | 119.86 |
Cash Flow / Debt | -2.35 |
Interest Coverage | -116.54 |
Financial Efficiency
Return on equity (ROE) is 22.79% and return on capital (ROIC) is -374.55%.
Return on Equity (ROE) | 22.79% |
Return on Assets (ROA) | -1.93% |
Return on Capital (ROIC) | -374.55% |
Revenue Per Employee | 34.69K |
Profits Per Employee | -752.37K |
Employee Count | 70 |
Asset Turnover | 0.09 |
Inventory Turnover | 21.51 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -40.46% in the last 52 weeks. The beta is 1.42, so Lucid Diagnostics 's price volatility has been higher than the market average.
Beta | 1.42 |
52-Week Price Change | -40.46% |
50-Day Moving Average | 0.91 |
200-Day Moving Average | 0.88 |
Relative Strength Index (RSI) | 28.6 |
Average Volume (20 Days) | 408.18K |
Income Statement
In the last 12 months, Lucid Diagnostics had revenue of $2.43M and earned -$52.67M in profits. Earnings per share was $-1.26.
Revenue | 2.43M |
Gross Profit | -3.55M |
Operating Income | -48.48M |
Net Income | -52.67M |
EBITDA | -49.75M |
EBIT | -48.48M |
Earnings Per Share (EPS) | -1.26 |
Balance Sheet
The company has $18.90M in cash and $15.26M in debt, giving a net cash position of $3.64M.
Cash & Cash Equivalents | 18.90M |
Total Debt | 15.26M |
Net Cash | 3.64M |
Retained Earnings | -150.74M |
Total Assets | 22.60M |
Working Capital | 2.58M |
Cash Flow
In the last 12 months, operating cash flow was -$32.82M and capital expenditures -$221.00K, giving a free cash flow of -$33.04M.
Operating Cash Flow | -32.82M |
Capital Expenditures | -221.00K |
Free Cash Flow | -33.04M |
FCF Per Share | -0.79 |
Margins
Gross margin is -146.25%, with operating and profit margins of -2.00K% and -2.17K%.
Gross Margin | -146.25% |
Operating Margin | -2.00K% |
Pretax Margin | -2.17K% |
Profit Margin | -2.17K% |
EBITDA Margin | -2.05K% |
EBIT Margin | -2.00K% |
FCF Margin | -1.36K% |
Dividends & Yields
LUCD does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -161.54% |
FCF Yield | -70.94% |
Analyst Forecast
The average price target for LUCD is $2.5, which is 220.5% higher than the current price. The consensus rating is "Buy".
Price Target | $2.5 |
Price Target Difference | 220.5% |
Analyst Consensus | Buy |
Analyst Count | 4 |
Scores
Altman Z-Score | -16.43 |
Piotroski F-Score | 4 |